This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 scFv-Fc to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD20 as well as the biological activity of IL2. This 2B8-Fc-hIL2 was at least equivalent to the commercial molecule in both binding to Daudi cells and activation of ADCC and may represent a promising plant-derived biopharmaceutical for the treatment of NHLs. This immunocytokine was designed for treating leukemias, lymphomas, rheumatoid arthritis, and other autoimmune diseases.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.